title: Growth outcome during GnRH agonist treatments for slowly progressive central precocious puberty.
abstract: BACKGROUND
  Gonadotropin-releasing hormone agonists (GnRHa) represent the gold-standard treatment for central precocious puberty (CPP). In CPP children, GnRHa treatment slows bone age progression and preserves adult height (Ht) by suppressing sexual steroid secretion. In some patients, however, GnRHa induce an inappropriate growth deceleration impairing Ht outcome. Furthermore, slowly progressive CPP (spCPP) forms were reported which do not need GnRHa treatment.
  
  
  METHODS
  We evaluated the growth outcome of 26 spCPP girls treated with triptorelin (TR) and 21 with leuprorelin acetate (LA) for 36.5 +/- 0.7 months.
  
  
  RESULTS
  GnRHa treatment induced a progressive growth deceleration in both spCPP groups. No difference in bone maturation was detected (p > 0.05; TR vs. LA group), however compared to LA, TR treatment resulted in significantly higher Ht after 24 months (p < 0.05; LA vs. TR group). Although target height (TH) standard deviation score (SDS) and predicted adult height (PAH)-SDS at diagnosis were similar in both spCPP groups (p > 0.05; LA vs. TR group), final height (FH-SDS) was lower in LA-treated subjects (p < 0.05; LA vs. TR group). In both spCPP groups, FH-SDS was significantly lower than TH-SDS (p < 0.001) but not lower than PAH-SDS at diagnosis (p > 0.05). Ht-SDS correlated with 17beta-estradiol (E(2)) blood levels in both spCPP groups (p < 0.0001) throughout GnRHa treatment, and E(2) values were higher in the TR- than in the LA-treated patients during the 12 months after GnRHa administration (p < 0.05; LA vs. TR group). GnRHa-induced E(2) secretion and Ht-SDS at GnRHa withdrawal correlated positively with FH (p < 0.01 and p < 0.001, respectively).
  
  
  CONCLUSIONS
  The effectiveness of GnRHa treatment in improving FH in spCPP girls was doubtful.
authors.affiliation: Pediatric Endocrine Center, Department of Pediatrics, University of Pisa, Pisa, Italy. massart@med.unipi.it
authors.forename: Francesco
authors.initials: F
authors.lastname: Massart
authors.forename: Giovanni
authors.initials: G
authors.lastname: Federico
authors.forename: Joshua Chuck
authors.initials: JC
authors.lastname: Harrell
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Saggese
mesh_terms: D000704:Analysis of Variance; D001827:Body Height / Q000187:drug effects; D001846:Bone Development / Q000187:drug effects; D002648:Child; D002657:Child Development / Q000187:drug effects*; D004958:Estradiol / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D005500:Follow-Up Studies; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D006801:Humans; D016729:Leuprolide / Q000627:therapeutic use*; D007986:Luteinizing Hormone / Q000097:blood; D011629:Puberty, Precocious / Q000188:drug therapy*; D012044:Regression Analysis; D013997:Time Factors; D016896:Treatment Outcome; D017329:Triptorelin Pamoate / Q000627:therapeutic use*
chemical_list: D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone; D004958:Estradiol; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D016729:Leuprolide